Epithalon

Overview

Epithalon (also spelled Epitalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly, often shortened to AEDG. It was designed by Vladimir Khavinson's group in St. Petersburg as a small synthetic counterpart to Epithalamin, a peptide extract prepared from animal pineal glands that the same group had studied earlier.

Research interest centers on aging biology. The most cited claims are that Epithalon switched on telomerase, the enzyme that rebuilds the protective caps at chromosome ends, in cultured human cells, and that it was associated with longer maximum lifespan and fewer tumors in some mouse strains.

The evidence needs to be read with one fact in front: almost all of it comes from a single research network led by Khavinson and his long-time collaborator Vladimir Anisimov, much of it in Russian journals or their English translations. Independent replication is sparse. There are no large, randomized, placebo-controlled human trials of synthetic Epithalon, and no study has shown that it slows human aging. For a broader look at how aging compounds are evaluated, see our review of NAD+ precursors and cellular aging.

Research history

Khavinson's program on so-called peptide bioregulators started with crude extracts from organs such as the thymus and pineal gland. Epithalamin, the pineal extract, was studied first. Epithalon was then produced as a defined synthetic peptide, reportedly based on the amino acid composition of that extract.

In 2002 and 2003 the group published a burst of papers. Anisimov, Khavinson and Italian collaborators reported reduced mammary tumor burden in HER-2/neu transgenic mice. A lifespan study in female SHR mice followed. In 2003 and 2004, two short reports in the Bulletin of Experimental Biology and Medicine described telomerase activation and telomere elongation in human fetal fibroblasts.

Since then, the same institutes have produced most of the follow-up work, often testing Epithalon alongside other short peptides from the same program. Outside groups have only occasionally published on it, and usually in cell or animal models.

What published studies have examined

Cell studies

• Telomerase in fibroblasts (2003). Khavinson, Bondarev and Butyugov reported that adding Epithalon to telomerase-negative human fetal fibroblast cultures induced expression of the telomerase catalytic subunit, enzyme activity and telomere elongation. The paper is two pages long and gives limited methodological detail.
• Replicative limit (2004). The same group reported that fetal lung fibroblasts exposed to Epithalon regained telomere length and went on for about 10 extra passages beyond untreated cells. This has not been widely reproduced by independent labs.
• Oocytes (2022). An independent team in China (Yue and colleagues) found that Epitalon added to culture medium reduced reactive oxygen species and some markers of damage in aging mouse eggs outside the body. This is a lab dish model and says nothing about lifespan.

Animal studies

• Lifespan in SHR mice (2003). Anisimov and colleagues gave 54 female mice Epithalon and compared them with 54 saline controls for life. Mean lifespan did not change. Maximum lifespan and survival of the longest-lived 10 percent rose modestly, chromosome aberrations in bone marrow fell, and leukemia was less frequent, while total tumor incidence was unchanged.
• Tumor model (2002). In HER-2/neu transgenic mice, the cumulative number and maximum size of mammary tumors were lower with Epithalon than with saline.

Human studies

The most cited human paper (Khavinson and Morozov, 2003) followed 266 older adults for 6 to 8 years and reported lower mortality in groups given peptide preparations. It tested Epithalamin, the pineal extract, and Thymalin, not synthetic Epithalon, and the report gives little detail on randomization, blinding or statistical methods. It cannot be treated as evidence for Epithalon itself.

Open questions

• Replication. The central telomerase finding rests on a small number of short reports from one group. Independent confirmation in human cells, with full methods and raw data, is the most obvious gap.
• Mechanism. How a four amino acid peptide would enter cells and alter gene expression is not established. The originating group has proposed that short peptides act on gene expression directly; outside labs have not shown this convincingly.
• Telomerase and cancer. Telomerase activation is a hallmark of most cancers. Whether switching it on in normal cells is safe is an open and serious question, even though the mouse tumor data from the originating group pointed the other way.
• Human evidence. There are no modern, registered, placebo-controlled trials of synthetic Epithalon with published results. Safety over long exposure in humans is unknown.
• Product quality. Material sold online varies. Our guide to what makes a peptide research grade covers what purity testing can and cannot confirm.